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INTRODUCTION
The main limitation of the classical basket- or paddle-type dissolution apparatus is the sink condition requirement because there is a high risk of quickly 
reaching the supersaturated concentration in a typical 1-L 
dissolution vessel. Furthermore, it is sometimes not possible 
to achieve sink conditions for active pharmaceutical 
ingredients (APIs) that are practically insoluble in aqueous 
solutions. In the past, the majority of research compounds 
had a relatively low molecular weight and acceptable 
solubility; however, the number of larger and less soluble 
molecules showing permeability or solubility-limited 
absorption has increased in recent years (2).
The open-type flow-through dissolution technique, 
being a dynamic system, more closely mimics the in vivo 
status of the body than the static-type classical paddle 
and basket apparatus. The dissolved API is removed and 
collected from the cells of the FTDE, which provides the 
possibility for dissolution of a new portion of the solid 
material, modeling absorption and elimination.
It is possible to combine spectroscopic imaging and FTDE 
to improve the possibilities for investigating the release of 
poorly soluble APIs from pharmaceutical tablets (3).
MATERIALS AND METHODS
Flow-Through Dissolution Technique
The experimental work was carried out on an open 
Sotax CE 7 smart-type flow-through dissolution 
apparatus. This type of equipment is designed for both 
online spectrophotometric and offline HPLC analysis. 
Online spectrophotometric measurement is a suitable 
tool for routine analysis, when the dissolution kinetics 
profile is known from previous measurements. The 
offline configuration is preferred for the discovery and 
preclinical/preformulation phases, when the evaluated 
candidates or salts have different dissolution kinetic 
profiles. The set flow rate was 4.0 mL/min to ensure 
suitable discriminative effect among the candidates; this 
is the lowest flow rate recommended by the European 
Pharmacopoeia and the USP. The temperature of the 
medium was 37.0 ± 0.5 °C. The scheme of the equipment 
is presented in Figure 1.
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Figure 1. Open-type FTDE.
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The fraction collector is designed with 60-mL tubes, thus 
the collection of all the fractions is possible with 15-min 
sampling intervals. If the sampling interval is increased to 
30 min, a representative sample is collected.
The end point of the studies was between 60 and 120 
min, so the maximum necessary dissolution medium 
is between 240 and 480 mL/cell. This low volume of 
dissolution medium is preferred when the price of special 
media (e.g., fasted-state simulated intestinal fluid, FaSSIF, 
and fed-state simulated intestinal fluid, FeSSIF) is high 
because good quality lecithin and Na-taurocholate are 
used for solution preparation. It is feasible to mimic in 
vivo conditions with the media selector tool. In that case, 
several solutions—from acidic to neutral—flow through 
the same cells. Some researchers (4) have coupled FTDE 
with a Caco-2 cell to obtain data on the absorption 
behavior of the APIs.
Because open-type equipment was used for the trials, 
the candidates met fresh dissolution medium during the 
study, providing a tool for studying new molecules with 
low aqueous solubility.
Different types of cells are available for testing powders, 
granules, solid dosage formulations, and patches. The 
most appropriate cell for discovery and preclinical/
preformulation activities is the powder cell. 
Since the particle size distribution of candidates has an 
impact on the solubility kinetics, it was measured by laser 
diffraction or by microscopic methods. The differences 
among particle size distributions were considered for the 
evaluation. 
Comparison of the Classical Dissolution 
Technique with Flow-Through Method
During classical dissolution experiments, the dissolution 
medium is practically permanent (except when a medium 
replacement is performed during the sampling period, 
but this replacement is not comparable to the conditions 
of a flow-through dissolution technique). That is why it is 
challenging to ensure the sink condition requirement in 
case of a BCS Class II API; it is very often feasible only with 
surfactants. Dissolution experiments performed with a 
high concentration of surfactant decrease the possibility 
of correlation with in vivo conditions.
Materials
Some model APIs with anti-inflammatory therapeutic 
effect were selected. 
• Model A: one chemical structure was evaluated.
• Model B: four different chemical structures 
 were tested.
• Model C: two different salts and the base form  
 of the API were compared and solubility in FaSSIF 
 and FeSSIF was evaluated.
Buffer solutions were prepared according to the USP 
recommendations (5). The FaSSIF and FeSSIF solutions 
were prepared based on the description of the USP 
working group (6) with high quality lecithin (Lipoid E PC S, 
Ludwigshafen, Germany) and Na-taurocholate (Prodotti 
Chimici e Alimentari, Basaluzzo, Italy). 
The analysis of samples was performed on an Agilent 
1200 HPLC with a gradient elution method. The HPLC 
column used for Models A and B was a C18 XTerra (5-
µm, 150 × 4.6 mm). The analysis was performed at 37 °C 
with a 20-µL injection volume and a flow rate of 0.8 mL/
min. The eluent A composition was water/acetonitrile/
methane sulfonic acid (1000:25:1, v/v/v), and the eluent 
B composition was water/acetonitrile/methane sulfonic 
acid (25:1000:1, v/v/v). The ratios of the A and B eluents 
of the gradient HPLC method are: 0 min (90:10); 11 min 
(0:100); 16 min (0:100); 16.5 min (90:10); and 23 min 
(90:10). The samples were analyzed at 220 nm with a UV 
detector. The concentrations of the standard calibration 
curve were 5, 10, and 25 µg/mL.
For the Model C materials, the same HPLC column was 
used. The HPLC analysis was performed at 37 °C with a 
10-µL injection volume and a flow rate of 0.8 mL/min. 
The A eluent composition was 5 mM KH2PO4/5 mM 
K2HPO4 containing water/acetonitrile (950:50, v/v), while 
the B eluent was acetonitrile. The ratios of the A and B 
eluents for the gradient HPLC method are: 0 min (100:0); 
10 min (0:100); 15 min (0:100); 16 min (100:0); and 21 min 
(100:0). The samples were analyzed at 250 nm with a UV 
detector. The concentrations of the standard calibration 
curve were 20, 40, and 85 µg/mL.
RESULTS AND DISCUSSION
Discovery Phase
Predicting how a drug will behave in humans before 
clinical testing requires a battery of sophisticated in 
vitro tests that complement traditional in vivo animal 
safety assessments (7). The quantities of promising new 
candidates available for early pharmaceutical evaluation 
are usually limited to between 10 and 20 mg during the 
lead optimization process. To choose the best compounds 
from a biopharmaceutical point of view, physicochemical 
parameters such as solubility, dissolution rate, 
hygroscopicity, lipophilicity, pKa, stability, polymorphism, 
and particle characteristics must be evaluated as early as 
possible and, above all, with the highest accuracy (8).
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For the success of the research, it is very important 
to initiate solubility kinetics studies in buffered and in 
biorelevant solutions (e.g., FaSSIF, FeSSIF) to estimate the 
in vivo behavior of the compounds as early as possible. 
Two main types of evaluation exist during the early and 
late discovery phases, formulation support and early 
biopharmaceutical evaluation of new candidates.
The particle size of the discovery candidates was less 
than 20 µm measured by optical microscope. During 
the comparison of several dissolution curves of different 
candidates, the particle size was also measured and 
evaluated. This is essential based on the Noyes–Whitney 
equation since dissolution rate depends on both the 
specific surface area and the particle size distribution.
On the basis of literature data (9), the greatest effect 
of particle size on absorption was simulated for low 
dose–low solubility drugs. In general, the sensitivity of 
absorption to particle size decreased with increasing dose 
or solubility. At a solubility of 1 mg/mL, particle size had 
practically no effect on the percentage of dose absorbed 
over the range of simulated doses (1–250 mg).
Formulation Support: Testing of Model A Material
Formulation development during early drug discovery and 
lead optimization involves several challenges including 
limited drug supply, the need for rapid turnaround, and 
limited development time. It is also desirable to develop 
initial formulations that will be representative of final 
commercial formulations (10).
The target of discovery is to screen many molecules as 
fast as possible. This activity can be helped if a solution 
formulation for the new candidates can be found. In that 
case, physical characterization such as determination 
of polymorphic forms and measurement of the particle 
size distribution within the suspension formulation is not 
necessary (11). The basic knowledge required to develop 
a solution formulation for new candidates is the pH-
dependent solubility profile. Measurement of the pH-
dependent solubility properties is rather difficult if the 
available quantity of the candidate is only 10 mg. Flow-
through dissolution is a very good tool in that case, since 
there is a possibility of initiating the solubility kinetics 
study from 1 mg API per powder cell. 
The pH-dependent solubility profile and pH range 
requirement of the administration route determine the 
pharmaceutical possibilities of the formulators. In the 
case of Model A material, the pH-dependent solubility 
profiles were measured at three different pH levels of 
1.2, 4.5, and 7.2. The cumulative flow-through dissolution 
curves are presented in Figure 2. The curves show that 
the dissolution profiles of Model A material are faster 
and better at pH 1.2 and 4.5, and the compound has 
very low solubility at pH 7.2. This low solubility at pH 7.2 
is a pharmaceutical challenge because a neutral pH was 
requested by pharmacologists for the planned nasal 
administration route. The formulation issue was solved 
with a low quantity of surfactant. The tolerability of the 
formulation was tested on an animal model.
Biopharmaceutical Evaluation of Discovery Model 
Material: Testing of Model B Material
The objective was to select the lead candidate, not only 
from biological efficacy and pharmacokinetics results but 
also from a biopharmaceutical assessment. This example 
illustrates that collaboration among chemists, biologists, 
pharmacologists, and pharmacists as early as possible is 
important to identify insoluble chemical scaffolds.
Even though solubility can be estimated from the 
computation of the effect of each functional group 
individually, an exact evaluation of the solubility of the 
complete chemical structure in an in vitro kinetics test 
at 37 °C was performed. These conditions are preferred 
to equilibrium solubility after 16 or 24 h, which has less 
pharmaceutical relevance. On the basis of chemical 
structure and pKa results (Figure 3), the best solubility 
kinetic profile was expected from Structure IV at pH 1.2 
in artificial gastric fluid. However, the fastest dissolution 
kinetics was measured for the Structure I. Structures III 
and IV showed interesting results with similar dissolution 
kinetics under acidic and almost neutral conditions as well.
The calculated or measured pKa values are available for 
candidates that can be ionized. From those values the 
possible absorption site of the candidates within the 
gastrointestinal tract can be evaluated. The main targets 
of the early biopharmaceutical evaluation are to measure 
the pH-dependent solubility profiles of the leads or scaffold 
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structures and to support the candidates that have better 
solubility properties on the estimated absorption site. The 
different chemical structures of Model B were evaluated 
on the basis of these considerations. The cumulative 
solubility curves (Figure 3) show that Model B Structure 
III has appropriate solubility at both pH 1.2 and 7.2, which 
is promising because the candidate can be found in a 
nonionized form (suitable for absorption) at pH 7.2 under 
fasted conditions. Model B Structure I has an excellent 
solubility at a pH of 1.2, but from pharmaceutical point 
of view, this form cannot be used because it can be found 
99.9% in ionized form. 
Structure II has pH-independent absorption, but its 
solubility is rather low at both pH 1.2 and 7.2, which is why 
this structure is not proposed for further development.
Structure IV has moderate and nearly similar solubility 
properties at pH 1.2 and 7.2; however, 36.5% of the 
candidate can be found in a nonionized form at pH 
7.2 according to the calculated pKa value. Because of 
the above mentioned facts, Structure IV has not been 
proposed for further development.
The flow-through dissolution technique is an excellent 
tool because the evaluation was available within a 
short time and it gave a good feedback to chemists and 
pharmacologists as well.
According to this approach, the new supported 
candidates were the ones that have acceptable aqueous 
solubility on the estimated place of the absorption. This is 
also very important from preclinical development point 
of view, since the costs can be reduced if, for example, 
particle size decrease can be omitted on the basis of the 
acceptable aqueous solubility property of the candidate. 
Preclinical Phase: Testing of Model C Material
Higher quantities of the selected APIs were available 
for several preclinical activities such as pharmaceutical 
evaluation of several salts versus base and formulations.
Comparison of Several Salts 
The flow-through dissolution study was performed on 
two salts (fumarate and disulfate) and the base form of 
the Model C. The results are presented in Figure 4. 
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The dissolution study was performed at pH 1.2, 3.0, and 
7.4 and at pH 7.4 with 0.5 % Tween 80. The flow-through 
dissolution curves show that the dissolution behavior of 
the two salt forms and the base form is similar (decreasing 
solubility from pH 1.2 to 7.2). However, the fumarate salt 
has the best dissolution rate at pH 7.4 when Tween 80 
was added to the dissolution medium. This fact was used 
during formulation development of the fumarate salt of 
Model C.
Flow-Through Dissolution Study in FaSSIF and 
FeSSIF Solutions
The food effect prediction for Model C as a fumarate 
salt was performed on the open-type FTDE. The most 
frequently used media are the fasted- and fed-state 
simulated small intestinal fluids (FaSSIF and FeSSIF) 
developed by Galia et al. (12).
The dissolution results, the calculated reaction speed 
constants, and the evaluation of the kinetics of the 
dissolution process are summarized in Table 1. The 
evaluation of the dissolution kinetics was done by 
calculation.
Evaluation of the Kinetic Order of Model C Material
After several minutes of lag time, a clear first-order 
kinetics was confirmed for the flow-through dissolution 
in the FeSSIF medium (r = 0.9889). But the kinetics in the 
FaSSIF medium correlates as first-order between 30 and 
60 min dissolution time and is pseudo first-order from 
90 min dissolution time (r = 0.9551). According to the 
results in Table 1, the higher lecithin and Na-taurocholate 
contents of the FeSSIF medium ensure first-order kinetics 
of the Model C material, but in the case of the FaSSIF 
medium, the dissolution of the API is limited in FaSSIF 
medium for a 90-min dissolution time.
Evaluation of the Food Effect of Model C Material 
A 1.7 times greater absorption (average of FeSSIF/FaSSIF 
ratio) is expected based on the in vitro flow-through 
dissolution results after a high fat breakfast, which means 
there is a slight risk for food effect. The FeSSIF/FaSSIF 
ratio measurement is standard during preformulation 
studies, but if the ratio is based on equilibrium solubility 
or on classical dissolution measurements, there is a high 
risk for much higher differences during clinical studies 
because classical approaches do not approximate the 
dynamic circumstances of the human body. Therefore, 
FTDE is proposed to measure the FeSSIF/FaSSIF ratio.
CONCLUSION
The flow-through dissolution technique is an excellent tool 
for evaluating several candidates in both the discovery 
and preclinical phases, in particular when low quantities 
of compound are available for pharmaceutical evaluation. 
This technique is able to support the development of a 
discriminative dissolution method, even if it is unfeasible 
with a classical dissolution approach in 500 mL or 1000 
mL of dissolution medium. 
This approach provides the possibility for preformulation 
experts to attain a pharmaceutical understanding of the 
molecules as early as possible. A basic knowledge of the 
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pH-dependent solubility of the API was available within a 
short time with an HPLC analysis, and the results made it 
possible to start the formulation approach.
The opened-type FTDE represents the dynamic system of 
the human body in a better way than the classical paddle 
or basket methods, which is why FTDE has a greater role 
during the discovery and preclinical studies, in particular 
for BCS Class II and IV candidates.
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Table 1. FaSSIF, FeSSIF Flow-Through Dissolution Results of Model C Material  
Dissolution medium FaSSIF, C0 = 1 mg
Time
(min)
Dissolved
(%)
Dissolved
(mg)
Remaining
mg (C)
Reaction speed constants
Evaluation 
of the 
kinetic
Zero order
       k =  
First order
k =
5 0.02 0.0002 0.9998 0.0040 0.0000
Lag Time
10 3.64 0.0364 0.9636 0.3640 0.0037
30 35.32 0.35323 0.6468 1.1774 0.0145
First-order45 48.48 0.48477 0.5152 1.0773 0.0147
60 57.74 0.57743 0.4226 0.9624 0.0144
90 65.40 0.65397 0.3460 0.7266 0.0118 Pseudo
first-order120 72.98 0.72977 0.2702 0.6081 0.0109
Dissolution medium FeSSIF, C0 = 1 mg
5 0.04 0.0004 0.9996 0.0080 0.0001
Lag Time
10 9.07 0.0907 0.9093 0.9073 0.0095
30 63.04 0.6304 0.3696 2.1012 0.0332
First-Order
45 76.54 0.7654 0.2346 1.7010 0.0322
60 87.33 0.8733 0.1267 1.4555 0.0344
90 93.95 0.9395 0.0605 1.0439 0.0312
120 100.51 1.0051 -0.0051 0.8376 –
t
CC −0
C
C
t
0log303.2
Table 1. FaSSIF, FeSSIF Flow-Through Dissolution Results of Model C Material  
